Multidrug transporters and alterations in sterol biosynthesis contribute to azole antifungal resistance in Candida parapsilosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 5942-5950

  Berkow, Elizabeth L ^a,b   Manigaba, Kayihura ^a,b   Parker, Josie E ^c   Barker, Katherine S ^a,b   Kelly, Stephen L ^c   Rogers, P David ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CDR1 PROTEIN; FLUCONAZOLE; ITRACONAZOLE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PYRROLE DERIVATIVE; STEROL; UNCLASSIFIED DRUG; VORICONAZOLE; ABC TRANSPORTER; ANTIFUNGAL AGENT; FUNGAL PROTEIN; OXIDOREDUCTASE; STEROL 14ALPHA DEMETHYLASE; STEROL DELTA-5 DESATURASE; TRANSACTIVATOR PROTEIN;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CDR1 GENE; ERG11 GENE; FUNGUS ISOLATION; GENE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; MDR1 GENE; MINIMUM INHIBITORY CONCENTRATION; MRR1 GENE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEROL ANALYSIS; STEROL SYNTHESIS; TAC1 GENE; UPC2 GENE; AGONISTS; BIOSYNTHESIS; CANDIDA; CANDIDIASIS; DNA SEQUENCE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION;

ANTIFUNGAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; OXIDOREDUCTASES; P-GLYCOPROTEIN; PHENOTYPE; SEQUENCE ANALYSIS, DNA; STEROL 14-DEMETHYLASE; STEROLS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 84942279101     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01358-15     Document Type: Article

References (27)

1. Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. 2012. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis 73:45-48. http://dx.doi.org/10.1016/j.diagmicrobio.2012.02.001.
2. Silva AP, Miranda IM, Guida A, Synnott J, Rocha R, Silva R, Amorim A, Pina-Vaz C, Butler G, Rodrigues AG. 2011. Transcriptional profiling of azole-resistant Candida parapsilosis strains. Antimicrob Agents Chemother 55:3546-3556. http://dx.doi.org/10.1128/AAC.01127-10.
3. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Baughman W, Stein B, Hollick R, Park BJ, Chiller T. 2012. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 50:3435-3442. http://dx.doi.org/10.1128/JCM.01283-12.
4. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36:1-53. http://dx.doi.org/10.3109/10408410903241444.
5. van Asbeck EC, Clemons KV, Stevens DA. 2009. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol 35:283-309. http://dx.doi.org/10.3109/10408410903213393.
6. Trofa D, Gácser A, Nosanchuk JD. 2008. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 21:606-625. http://dx.doi.org/10.1128/CMR.00013-08.
7. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535. http://dx.doi.org/10.1086/596757.
8. MacPherson S, Akache B, Weber S, De Deken X, Raymond M, Turcotte B. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob Agents Chemother 49:1745-1752. http://dx.doi.org/10.1128/AAC.49.5.1745-1752.2005.
9. Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, Morschhauser J, Rogers PD. 2012. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot Cell 11:1289-1299. http://dx.doi.org/10.1128/EC.00215-12.
10. Warrilow AG, Martel CM, Parker JE, Melo N, Lamb DC, Nes WD, Kelly DE, Kelly SL. 2010. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother 54:4235-4245. http://dx.doi.org/10.1128/AAC.00587-10.
11. Kelly SL, Lamb DC, Kelly DE, Manning NJ, Loeffler J, Hebart H, Schumacher U, Einsele H. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett 400:80-82. http://dx.doi.org/10.1016/S0014-5793(96)01360-9.
12. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39:2378-2386. http://dx.doi.org/10.1128/AAC.39.11.2378.
13. Lopez-Ribot JL, McAtee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, Patterson TF. 1998. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 42:2932-2937.
14. Morschhäuser J, Barker KS, Liu TT, BlaB-Warmuth J, Homayouni R, Rogers PD. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 3:e164. http://dx.doi.org/10.1371/journal.ppat.0030164.
15. Coste A, Turner V, Ischer F, Morschhäuser J, Forche A, Selmecki A, Berman J, Bille J, Sanglard D. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172:2139-2156.
16. Grossman NT, Pham CD, Cleveland AA, Lockhart SR. 2014. Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system. Antimicrob Agents Chemother 59:1030-1037. http://dx.doi.org/10.1128/AAC.04613-14.
17. Flowers SA, Colón B, Whaley SG, Schuler MA, Rogers PD. 2015. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother 59:450-460. http://dx.doi.org/10.1128/AAC.03470-14.
18. Reuss O, Vik A, Kolter R, Morschhäuser J. 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341:119-127. http://dx.doi.org/10.1016/j.gene.2004.06.021.
19. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Schmitt ME, Brown TA, Trumpower BL. 1990. A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucleic Acids Res 18:3091-3092. http://dx.doi.org/10.1093/nar/18.10.3091.
21. Dunkel N, Liu TT, Barker KS, Homayouni R, Morschhäuser J, Rogers PD. 2008. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot Cell 7:1180-1190. http://dx.doi.org/10.1128/EC.00103-08.
22. Amberg DC, Burke DJ, Strathern JN. 2006. Isolation of yeast genomic DNA for Southern blot analysis. CSH Protoc 2006:pdb.prot4149.
23. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE. 1995. Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol. Biochem Biophys Res Commun 207:910-915. http://dx.doi.org/10.1006/bbrc.1995.1272.
24. Hiller D, Sanglard D, Morschhäuser J. 2006. Overexpression of the MDR1 gene is sufficient to confer increased resistance to toxic compounds in Candida albicans. Antimicrob Agents Chemother 50:1365-1371. http://dx.doi.org/10.1128/AAC.50.4.1365-1371.2006.
25. White TC, Marr KA, Bowden RA. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11:382-402.
26. Watson PF, Rose ME, Ellis SW, England H, Kelly SL. 1989. Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals. Biochem Biophys Res Commun 164:1170-1175. http://dx.doi.org/10.1016/0006-291X(89)91792-0.
27. Hull CM, Bader O, Parker JE, Weig M, Gross U, Warrilow AG, Kelly DE, Kelly SL. 2012. Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Antimicrob Agents Chemother 56:6417-6421. http://dx.doi.org/10.1128/AAC.01145-12.